Qianxing Mo

Senior Member

H Lee Moffitt Cancer Center and Research Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (21)

Year:

2026

Venetoclax (VEN) combined with hypomethylating agents (HMA) improves outcomes for patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, yet overall survival (OS) remains variable. We analyzed 506 AML patients treated with front-line HMA/VEN at Moffitt Cancer Center to develop a genetics-based prognostic model. In multivariate analysis, mutations in TP53, KRAS, JAK2, U2AF1, CBL and cytogenetic lesions del(7q)/-7, del(17p)/-17/i(17q), del(20q), and MECOM rearrangements predicted inferior OS, whereas IDH1/2 mutations were favorable. A point-based system stratified patients into low-, intermediate-, and high-risk groups with median OS of 54.2, 22.3, and 7.5 months, respectively, (p<0.0001; C-index 0.648). External validation (n=126) retained prognostic separation (median OS 24.7, 17.4, and 4.3 months, p=0.0005; C-index 0.626). Compared to existing HMA/VEN-specific models, our model demonstrated superior low- vs. intermediate-risk discrimination (31.9-month separation, p=0.002; HR=0.45, p=0.003), with comparable C-index. Our model supports personalized risk stratification for HMA/VEN-treated AML, pending broader validation.

Year:

2026

Background Cancer-related fatigue (fatigue) is a common and persistent symptom after cancer treatment, yet the role of genetic susceptibility remains unclear. Methods We used data from a prospective cohort study called the ColoCare Study, conducted over 5 US sites and Germany. Fatigue was assessed at 5 time points using the European Organisation for the Research and Treatment of Cancer Core Quality of Life Questionnaire fatigue subscale and analyzed as (1) a binary summary measure of the trajectory from diagnosis into survivorship (defined as severe: yes/no), (2) a mean score across all time points, and (3) the highest (ie, worst) score across all time points. We genotyped samples using the Illumina Infinium Global Diversity Array kit with imputation using the National Institutes of Health TOPMed reference panel to conduct a genome-wide association study. The Sum of Single Effects was used to identify independent secondary signals. Transcriptome-wide association studies using the S-PrediXcan and MultiXcan methods were conducted to examine genetic regulation of gene expression. The COLOC package assessed whether variants identified in the genome-wide association study influence gene expression through colocalization analysis. Results Among 1219 participants, 31.0% experienced severe fatigue over the course of their disease. A locus near LINC02505 on chromosome 4 was associated with severe fatigue (rs6531463; odds ratio = 3.25, P = 3.88 × 10−8). When modeling mean fatigue levels, strongly associated variants were identified in or near NEK10 and SLC4A7. Integrative analyses linked the predicted expression of NEK10 in liver tissue to risk of fatigue (P < 4.36 × 10−6). Colocalization analysis identified genetic loci and gene expression near NEK10 (posterior probabilities >0.9). Conclusions This study identified novel genetic loci associated with fatigue in patients with colorectal cancer and may be useful for identifying high-risk individuals for preventative strategies.

Year:

2025

Background Leptomeningeal disease (LMD) from solid tumors has a dismal prognosis, even following treatment with anti-PD-1 therapy. We performed a phase IB study evaluating the safety of Avelumab with whole brain radiotherapy (WBRT) in LMD (NCT03719768). Methods Fifteen patients were enrolled with LMD from breast, lung, nasopharyngeal, ovarian, and pancreatic tumors. Patients were treated with Avelumab with WBRT, with the first infusion of Avelumab starting 14 days pre-WBRT and continuing during and post-WBRT for up to 5 cycles. Primary endpoints were safety and 3-month OS (OS3). Secondary endpoints included assessment of immune cells in the cerebrospinal fluid (CSF) using single-cell RNA-sequencing (scRNA-Seq) pre- and post-last treatment of Avelumab. Results DLTs occurred in 2 patients, ie, adrenal insufficiency, hypothyroidism, and pneumonitis. Treatment-related toxicities occurred in 5 patients with grade 1/2 and 5 patients with grade 3/4. Immune-related adverse events occurred in 5 patients with grade 1/2 and 3 patients with grade 3/4. The OS3 was 67% (10 of the 15; 95% CI: 38%–84%). Median-OS was 3.85 months (95% CI: 0.9–34.4 months) and median-PFS was 3.85 months (95% CI: 0.9–12.1 months). scRNA-Seq analysis of CSF pre- and post-last-treatment showed Avelumab + WBRT stimulated an adaptive immune response associated with a decrease in regulatory T cells (Tregs), among other changes in the expression of immune checkpoints on CD8 + T cells and macrophages. Conclusions The combination of Avelumab and WBRT is safe and demonstrates activity in patients with LMD. The identification of high levels of Tregs and macrophages in the CSF of LMD patients offers future avenues for therapeutic development.

Year:

2025

Background/Objectives: Through survey and analysis of pancreas cancer patient–caregiver dyads, we aimed to identify patient and caregiver characteristics that influence and determine the impact of caregiver coping strategies, self-esteem, and resilience on caregiver distress. Methods: This was a cross-sectional, observational study including pancreatic cancer patients and their caregivers. Demographics of patients and caregivers were collected. Caregivers completed validated instruments (National Comprehensive Cancer Network (NCCN) Distress Thermometer, Caregiver Reaction Assessment (CRA), Perceived Stress Scale 4 (PSS-4), Patient Reported Outcomes Measurement Information System-Anxiety/Depression Short Form (PROMIS-Anxiety/Depression), Brief Resilience Scale (BRS), Zarit Caregiver Burden Interview (CBI-12), and Brief Coping Orientation to Problems Experienced (COPE)) investigating anxiety, depression, perceived stress, caregiver burden, use of approach and avoidant coping, resilience, and self-esteem. Descriptive statistics, univariate, and multiple linear regression models were used to analyze the data. Results: One hundred and fourteen patient–caregiver dyads were included in this study. The majority of patients were male (55%), 65% of caregivers were female, and 64% of patients were receiving palliative intent treatment. Younger caregiver age, more personal care tasks, higher patient distress, and caregiving for a parent were characteristics related to caregiver avoidant coping. Fewer caregiving activities and early clinical stage were associated with caregiver approach coping. High caregivers’ self-esteem was significantly associated with fewer personal care tasks to perform and with caregivers of patients with higher levels of education. Avoidant coping and low resilience were both significantly correlated to distress, anxiety, depression, caregiver burden, and perceived stress. Additionally, low self-esteem was associated with a high perceived caregiver burden. Conclusions: Overall, caregiver factors such as age, relationship with the patient, and number of care tasks and activities influence caregivers coping and self-esteem. Additionally, patient education and clinical stage impacted caregiver coping and self-esteem. Developing interventions to address caregiver coping, self-esteem, and resilience will prove beneficial in improving caregiver distress, anxiety, depression, burden, and perceived stress.

Year:

2025

Directed acyclic graph for Cox proportional hazards regression. Directed acyclic graph representing all variables considered in building multivariable models for the Cox proportional hazards regression representing the associations of muscle changes with PDAC outcomes.

Year:

2025

Directed acyclic graph for generalized linear model. Directed acyclic graph representing all variables considered in building multivariable models for the generalized linear models representing the associations of PDAC diagnosis with post-diagnosis muscle changes.

Year:

2025

Background: Muscle loss influences pancreatic ductal adenocarcinoma (PDAC) outcomes, but treatment-related edema may cause overestimation of total skeletal muscle area (tSMA), confounding our understanding of muscle changes. However, no studies have quantified the impact of edema on tSMA and psoas skeletal muscle area (pSMA) changes. Thus, we sought to (i) assess the impact of edema on tSMA and pSMA changes between diagnosis and follow-up and (ii) explore the utility of pSMA as a clinically relevant measure of muscle and muscle loss among patients with PDAC. Methods: Body composition was measured using CT scans at diagnosis and follow-up from 95 patients enrolled in the Florida Pancreas Collaborative cohort study. Edema was assessed by opacifications in subcutaneous fat, and tSMA and pSMA changes were expressed as percent change between diagnosis and follow-up. We used multivariable generalized linear models to estimate mean tSMA and pSMA changes overall and by edema status. Spearman correlation was used to measure interrelationships of tSMA and pSMA. Results: tSMA increased between diagnosis and follow-up (Δ = 0.66) but only in patients with edema (Δ = 3.35) whereas non-edematous patients lost tSMA (Δ = −2.03). Conversely, pSMA decreased regardless of edema status. Furthermore, tSMA and pSMA were strongly correlated overall ( r = 0.75) and in non-edematous patients ( r = 0.83). Conclusions: Edema inflated estimates of tSMA at follow-up in patients with PDAC, but pSMA was impervious to edema and may represent a suitable proxy for tSMA. Impact: pSMA is a reliable measure of muscle and muscle loss and should be considered in future studies assessing muscle loss in patients with PDAC.

Year:

2025

Pancreatic ductal adenocarcinoma is projected to become the second leading cause of cancer-related deaths by 2040, with the highest disease burden expected amongst Non-Hispanic Blacks. One of the most significant predictors of poor outcomes is the presence of cancer-associated cachexia (CCa). Yet, race- and ethnicity-specific biomarkers for early CCa diagnosis are lacking. Thus, evaluated a panel of candidate biomarkers of CCa in a diverse cohort of pre-treatment serum. Our study shows that GDF-15 was associated with cachexia severity, was superior to standard CCa-associated biomarkers at classifying cachexia, and differentiated between non-cachexia and pre-cachexia status, but only among Hispanic/Latinx and non-Hispanic Whites. Furthermore, high GDF-15 levels at diagnosis were associated with a ~ 2-fold increase in weight loss over the 6 months post-diagnosis. Thus, GDF-15 may be a potential biomarker for pre-cachexia (prior to weight loss) in the White and the Hispanic population, but not Black individuals. These findings underscore the fact that enrollment of minority individuals in clinical trials to evaluate treatments for CCa is of utmost importance.

Year:

2025

PURPOSE Ruxolitinib improves splenomegaly and disease-related symptoms in most patients with myelofibrosis (MF), and it has been associated with a survival benefit in higher-risk patients with splenomegaly. Spleen volume reduction has been associated with a survival benefit in ruxolitinib-treated patients; however, its use as a surrogate is limited. We hypothesized that an anti-inflammatory response to ruxolitinib would correlate with improved patient outcomes. METHODS We interrogated serum albumin, an acute phase reactant and marker of nutritional status in 590 patients with MF and analyzed differential trajectories of albumin on the basis of ruxolitinib treatment. Additionally, we assessed the prognostic role of baseline albumin and change in albumin. RESULTS We found that serum albumin levels tend to decrease in patients with MF; however, this tendency is abrogated by ruxolitinib treatment. To that end, baseline serum albumin level correlates with overall survival (OS) in patients with MF, independent of the variables that comprise the dynamic international prognostic scoring system; however, this correlation is limited to ruxolitinib-naïve patients. In ruxolitinib-treated patients, the change in serum albumin after ruxolitinib treatment, rather than the baseline value, is associated with improved OS, a finding not seen in ruxolitinib-naïve patients. CONCLUSION These findings suggest that serum albumin, a ubiquitously available laboratory value, has specific relevance in patients with MF and reflects therapeutic response to ruxolitinib.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (28)

Somedeb Ball

Vanderbilt University Medical Center

UNITED STATES
View details

Jose G. Trevino

Virginia Commonwealth University

UNITED STATES
View details

Rami Komrokji

Vice chair

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Sylvia Crowder

Assistant Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Tiago Biachi de Castria

Associate Professor

University of South Florida

UNITED STATES
View details

Xuefeng Wang

Associate Member/Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Elizabeth Hyjek

Associate Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Sung Yun Jung

Associate Professor

Baylor College of Medicine

UNITED STATES
View details

Robert Macaulay

Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Ghulam Rasool

Assistant Member

Moffitt Cancer Center

UNITED STATES
View details

Harshani Lawrence

Scientific and Managing Director, Chemical Biology Core

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Vic VELANOVICH

University of South Florida

UNITED STATES
View details

Sarah Judge

Research Assistant Professor

University of Florida

UNITED STATES
View details

Dae Hyun Lee

Assistant Professor of Medicine

University of Pennsylvania

UNITED STATES
View details

Erika Eksioglu

Independent investigator/researcher

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Daniel Murphy

Professor of Lung Cancer & Mesothelioma

University of Glasgow

UNITED KINGDOM
View details

Kun Jiang

-

UNITED STATES
View details

Patricia Castro

Associate Professor

Baylor College of Medicine

UNITED STATES
View details

Andrew Judge

Professor

University of Florida

UNITED STATES
View details

Xiaoqing Yu

Associate Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Jose Pimiento

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Dung-Tsa Chen

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Paul Stewart

Research Associate Professor

University of Utah

UNITED STATES
View details

Liang Wang

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Christopher J. Whelan

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Christopher Cubitt

Core Staff Scientist

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Aleksandra Karolak

Assistant Professor - Secondary Appointment

Moffitt Cancer Center

UNITED STATES
View details

Daesung Lee

-

UNITED STATES
View details